当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
John A Smith, Emily B Johnson
This article provides a comprehensive overview of the research advancements in understanding and intervening in BRCA gene mutations associated with breast cancer. The discovery of BRCA1 and BRCA2 genes marked a pivotal moment in cancer genetics, unraveling the genetic landscape of hereditary breast and ovarian cancers. Over the years, diagnostics, risk assessment strategies, and targeted therapies have evolved, significantly impacting patient care and outcomes. This article highlights the progress made in this field, discusses challenges, and outlines future directions for research and interventions aimed at mitigating the impact of BRCA gene mutations on breast cancer. Over the years, extensive research has shed light on the genetic underpinnings of breast cancer, particularly mutations in the BRCA1 and BRCA2 genes. These mutations are associated with a significantly increased risk of developing breast and ovarian cancers. The journey of understanding and intervening in BRCA gene mutations has been a dynamic one, marked by breakthroughs in genetics, diagnostics, and targeted therapies. This article provides an overview of the research progress in advancing our understanding of BRCA gene mutations and the interventions developed to combat associated breast cancer risks